This study is exploring a new way to give the chemotherapy drug, Gemcitabine, to patients with pancreatic cancer. Instead of the usual method, it uses a special tube called the Extroducer® Infusion Catheter System to put the medicine directly into or near the tumor, which is a lump of cancer cells. The study involves patients whose cancer cannot be cut out with surgery. Over about 8-9 months, patients will have four treatment sessions, happening every two weeks. Different groups will try increasing doses of Gemcitabine (100 mg, 200 mg, and 400 mg) to see how much is safe. After all groups finish, doctors will decide if the treatment is safe and how well it works.

• Participating in the study means about 8-9 months of involvement.
• Patients will have four treatment sessions, spaced two weeks apart.
• Safety checks are done after each group finishes to decide next steps.